Large gap with delayed quotes
|
Last quote
04/25/2026
-
02:00:00
|
Bid
04/27/2026 -
14:57:00
|
Bid Volume |
Ask
04/27/2026 -
14:57:00
|
Ask Volume |
|---|---|---|---|---|
|
23.90
-0.09
(
-0.38% )
|
23.93
|
100 |
24.40
|
1,000 |
Analysis date: 24.04.2026
Global Evaluation
Neutral
Neutral
The stock is classified in the neutral zone since 17.04.2026.
Interest
Very strong
Very strong
Four stars since 17.04.2026.
Earnings Rev Trend
Positive
Positive
Compared to seven weeks ago, the analysts have raised their earnings per share estimates. This positive trend began 09.01.2026 at a price of 23.60.
Evaluation
Undervalued
Undervalued
Based on its growth potential and our own criteria, we believe the share price is currently moderately undervalued.
MT Tech Trend
Positive
Positive
The dividend-adjusted forty day technical trend is positive since 14.04.2026.
4wk Rel Perf
30.56%
30.56%
The four-week dividend-adjusted overperformance versus SP500 is 30.56%.
Sensibility
High
High
High, no change over 1 year.
Bear Market Factor
Middle
Middle
On average, the stock is likely to decline with the index.
Bad News Factor
Low
Low
When the stock's pressure is specific, the market sanction on average is 4.50%.
Mkt Cap in $bn
4.42
4.42
With a market capitalization between $2 & $8bn, LEGEND BIOTECH is considered a mid-cap stock.
G/PE Ratio
1.87
1.87
A ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) higher than 1.6 often suggests the projected growth is a result of a base effect, meaning the company can often be in a turn around situation. In this case, the estimated PE is a better indicator of a stock's expected growth than the Long Term Growth (LT Growth).
LT P/E
13.42
13.42
The estimated PE is for the year 2028.
LT Growth
25.10%
25.10%
The annualized growth estimate is for the current year to 2028.
Avg. Nb analysts
16
16
Over the last seven weeks, an average of 16 analysts provided earnings per share estimates.
Dividend Yield
0.00%
0.00%
The company is not paying a dividend.
Beta
46
46
For 1% of index variation, the stock varies on average by 0.46%.
Correlation
0.12
0.12
Stock movements are totally independent of index variations.
Value at Risk
10.17
10.17
The value at risk is estimated at USD 10.17. The risk is therefore 42.57%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
First Analysis Date
22.09.2023
22.09.2023